vs
Side-by-side financial comparison of Medtronic (MDT) and PNC Financial Services (PNC). Click either name above to swap in a different company.
Medtronic is the larger business by last-quarter revenue ($9.0B vs $6.1B, roughly 1.5× PNC Financial Services). PNC Financial Services runs the higher net margin — 33.5% vs 15.3%, a 18.2% gap on every dollar of revenue. On growth, PNC Financial Services posted the faster year-over-year revenue change (9.1% vs 6.6%). Over the past eight quarters, PNC Financial Services's revenue compounded faster (8.6% CAGR vs 5.3%).
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.
MDT vs PNC — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.0B | $6.1B |
| Net Profit | $1.4B | $2.0B |
| Gross Margin | 65.8% | — |
| Operating Margin | 18.8% | 38.4% |
| Net Margin | 15.3% | 33.5% |
| Revenue YoY | 6.6% | 9.1% |
| Net Profit YoY | 8.2% | 25.0% |
| EPS (diluted) | $1.07 | $4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.0B | $6.1B | ||
| Q3 25 | $8.6B | $5.9B | ||
| Q2 25 | $8.9B | $5.7B | ||
| Q1 25 | $8.3B | $5.5B | ||
| Q4 24 | $8.4B | $5.6B | ||
| Q3 24 | $7.9B | $5.4B | ||
| Q2 24 | $8.6B | $5.4B | ||
| Q1 24 | $8.1B | $5.1B |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $1.1B | $1.6B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $654.0M | $1.5B | ||
| Q1 24 | $1.3B | $1.3B |
| Q4 25 | 65.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 64.8% | — | ||
| Q1 25 | 66.5% | — | ||
| Q4 24 | 64.9% | — | ||
| Q3 24 | 65.1% | — | ||
| Q2 24 | 64.5% | — | ||
| Q1 24 | 65.6% | — |
| Q4 25 | 18.8% | 38.4% | ||
| Q3 25 | 16.8% | 38.7% | ||
| Q2 25 | 16.1% | 35.8% | ||
| Q1 25 | 19.9% | 33.9% | ||
| Q4 24 | 19.0% | 34.2% | ||
| Q3 24 | 16.1% | 34.3% | ||
| Q2 24 | 12.3% | 33.6% | ||
| Q1 24 | 18.3% | 32.2% |
| Q4 25 | 15.3% | 33.5% | ||
| Q3 25 | 12.1% | 30.8% | ||
| Q2 25 | 11.8% | 29.0% | ||
| Q1 25 | 15.6% | 27.5% | ||
| Q4 24 | 15.1% | 29.2% | ||
| Q3 24 | 13.2% | 27.7% | ||
| Q2 24 | 7.6% | 27.3% | ||
| Q1 24 | 16.3% | 26.1% |
| Q4 25 | $1.07 | $4.88 | ||
| Q3 25 | $0.81 | $4.35 | ||
| Q2 25 | $0.81 | $3.85 | ||
| Q1 25 | $1.01 | $3.51 | ||
| Q4 24 | $0.99 | $3.76 | ||
| Q3 24 | $0.80 | $3.49 | ||
| Q2 24 | $0.50 | $3.39 | ||
| Q1 24 | $0.99 | $3.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.3B | — |
| Total DebtLower is stronger | $27.7B | $57.1B |
| Stockholders' EquityBook value | $48.7B | $60.6B |
| Total Assets | $91.3B | $573.6B |
| Debt / EquityLower = less leverage | 0.57× | 0.94× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.3B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $7.9B | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | $7.8B | — | ||
| Q2 24 | $8.0B | — | ||
| Q1 24 | $8.3B | — |
| Q4 25 | $27.7B | $57.1B | ||
| Q3 25 | $26.2B | $62.3B | ||
| Q2 25 | $25.6B | $60.4B | ||
| Q1 25 | $24.0B | $60.7B | ||
| Q4 24 | $24.6B | $61.7B | ||
| Q3 24 | $26.3B | $68.1B | ||
| Q2 24 | $23.9B | $71.4B | ||
| Q1 24 | $24.2B | $72.7B |
| Q4 25 | $48.7B | $60.6B | ||
| Q3 25 | $47.9B | $59.0B | ||
| Q2 25 | $48.0B | $57.6B | ||
| Q1 25 | $49.4B | $56.4B | ||
| Q4 24 | $48.5B | $54.4B | ||
| Q3 24 | $47.9B | $55.7B | ||
| Q2 24 | $50.2B | $52.6B | ||
| Q1 24 | $51.8B | $51.3B |
| Q4 25 | $91.3B | $573.6B | ||
| Q3 25 | $91.0B | $568.8B | ||
| Q2 25 | $91.7B | $559.1B | ||
| Q1 25 | $90.0B | $554.7B | ||
| Q4 24 | $90.0B | $560.0B | ||
| Q3 24 | $89.7B | $564.9B | ||
| Q2 24 | $90.0B | $556.5B | ||
| Q1 24 | $90.8B | $566.2B |
| Q4 25 | 0.57× | 0.94× | ||
| Q3 25 | 0.55× | 1.06× | ||
| Q2 25 | 0.53× | 1.05× | ||
| Q1 25 | 0.49× | 1.08× | ||
| Q4 24 | 0.51× | 1.13× | ||
| Q3 24 | 0.55× | 1.22× | ||
| Q2 24 | 0.48× | 1.36× | ||
| Q1 24 | 0.47× | 1.42× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $925.0M | $757.0M |
| Free Cash FlowOCF − Capex | $457.0M | — |
| FCF MarginFCF / Revenue | 5.1% | — |
| Capex IntensityCapex / Revenue | 5.2% | — |
| Cash ConversionOCF / Net Profit | 0.67× | 0.37× |
| TTM Free Cash FlowTrailing 4 quarters | $5.2B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $925.0M | $757.0M | ||
| Q3 25 | $1.1B | $2.7B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.6B | $-509.0M | ||
| Q4 24 | $958.0M | $1.8B | ||
| Q3 24 | $986.0M | $3.3B | ||
| Q2 24 | $2.8B | $1.0B | ||
| Q1 24 | $2.5B | $1.8B |
| Q4 25 | $457.0M | — | ||
| Q3 25 | $584.0M | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $554.0M | — | ||
| Q3 24 | $466.0M | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | 5.1% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | 25.3% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 27.4% | — | ||
| Q1 24 | 26.3% | — |
| Q4 25 | 5.2% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 5.0% | — | ||
| Q1 24 | 4.3% | — |
| Q4 25 | 0.67× | 0.37× | ||
| Q3 25 | 1.05× | 1.46× | ||
| Q2 25 | 2.39× | 0.90× | ||
| Q1 25 | 1.99× | -0.34× | ||
| Q4 24 | 0.75× | 1.11× | ||
| Q3 24 | 0.95× | 2.18× | ||
| Q2 24 | 4.25× | 0.70× | ||
| Q1 24 | 1.87× | 1.31× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
PNC
| Corporate Institutional Banking Segment | $3.0B | 50% |
| Other | $2.5B | 42% |
| Interchange Fees | $181.0M | 3% |
| Asset Management Fees And Brokerage Fees | $155.0M | 3% |
| Net Credit Card Fees | $59.0M | 1% |
| Merchant Fees | $32.0M | 1% |
| Commercial And Residential Mortgage Banking Fees | $25.0M | 0% |
| Cash And Cash Management Fees Other | $20.0M | 0% |
| Lending And Deposit Services Other | $18.0M | 0% |
| Treasury Management Fees | $10.0M | 0% |
